aluates Reports

$ 0.0

Automative

Global GLP-1 Agonists for Obesity Market Research Report 2024

Published Date: April 2024

Report Code: QYRE-Auto-6Q17184

BUY CHAPTERS

Global GLP-1 Agonists for Obesity Market Research Report 2024

Code: QYRE-Auto-6Q17184

Report

April 2024

Pages:67

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novo

Novo Nordisk

Eli Lilly

Huadong Medicine

Shanghai Benemae Pharmaceutical Corporation

GLP-1 Agonists for Obesity Market

GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists have been approved to help treat obesity. GLP-1 agonists have been shown to be effective in promoting weight loss in preclinical and clinical studies.

The global GLP-1 Agonists for Obesity market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for GLP-1 Agonists for Obesity is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for GLP-1 Agonists for Obesity is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of GLP-1 Agonists for Obesity include Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for GLP-1 Agonists for Obesity, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Agonists for Obesity.

The GLP-1 Agonists for Obesity market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global GLP-1 Agonists for Obesity market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the GLP-1 Agonists for Obesity manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of GLP-1 Agonists for Obesity Market Report

Report Metric	Details
Report Name	GLP-1 Agonists for Obesity Market
Segment by Type	Semaglutide Tirzepatide Liraglutide Benaglutide
Segment by Application	Hospital Pharmaty Retail Pharmaty Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of GLP-1 Agonists for Obesity manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of GLP-1 Agonists for Obesity in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the GLP-1 Agonists for Obesity Market report?

Ans: The main players in the GLP-1 Agonists for Obesity Market are Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation

What are the Application segmentation covered in the GLP-1 Agonists for Obesity Market report?

Ans: The Applications covered in the GLP-1 Agonists for Obesity Market report are Hospital Pharmaty, Retail Pharmaty, Others

What are the Type segmentation covered in the GLP-1 Agonists for Obesity Market report?

Ans: The Types covered in the GLP-1 Agonists for Obesity Market report are Semaglutide, Tirzepatide, Liraglutide, Benaglutide

1 GLP-1 Agonists for Obesity Market Overview

1.1 Product Definition

1.2 GLP-1 Agonists for Obesity by Type

1.2.1 Global GLP-1 Agonists for Obesity Market Value Comparison by Type (2024-2030)

1.2.2 Semaglutide

1.2.3 Tirzepatide

1.2.4 Liraglutide

1.2.5 Benaglutide

1.3 GLP-1 Agonists for Obesity by Application

1.3.1 Global GLP-1 Agonists for Obesity Market Value by Application (2024-2030)

1.3.2 Hospital Pharmaty

1.3.3 Retail Pharmaty

1.3.4 Others

1.4 Global GLP-1 Agonists for Obesity Market Size Estimates and Forecasts

1.4.1 Global GLP-1 Agonists for Obesity Revenue 2019-2030

1.4.2 Global GLP-1 Agonists for Obesity Sales 2019-2030

1.4.3 Global GLP-1 Agonists for Obesity Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 GLP-1 Agonists for Obesity Market Competition by Manufacturers

2.1 Global GLP-1 Agonists for Obesity Sales Market Share by Manufacturers (2019-2024)

2.2 Global GLP-1 Agonists for Obesity Revenue Market Share by Manufacturers (2019-2024)

2.3 Global GLP-1 Agonists for Obesity Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of GLP-1 Agonists for Obesity, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of GLP-1 Agonists for Obesity, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of GLP-1 Agonists for Obesity, Product Type & Application

2.7 Global Key Manufacturers of GLP-1 Agonists for Obesity, Date of Enter into This Industry

2.8 Global GLP-1 Agonists for Obesity Market Competitive Situation and Trends

2.8.1 Global GLP-1 Agonists for Obesity Market Concentration Rate

2.8.2 The Global 5 and 10 Largest GLP-1 Agonists for Obesity Players Market Share by Revenue

2.8.3 Global GLP-1 Agonists for Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global GLP-1 Agonists for Obesity Market Scenario by Region

3.1 Global GLP-1 Agonists for Obesity Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global GLP-1 Agonists for Obesity Sales by Region: 2019-2030

3.2.1 Global GLP-1 Agonists for Obesity Sales by Region: 2019-2024

3.2.2 Global GLP-1 Agonists for Obesity Sales by Region: 2025-2030

3.3 Global GLP-1 Agonists for Obesity Revenue by Region: 2019-2030

3.3.1 Global GLP-1 Agonists for Obesity Revenue by Region: 2019-2024

3.3.2 Global GLP-1 Agonists for Obesity Revenue by Region: 2025-2030

3.4 North America GLP-1 Agonists for Obesity Market Facts & Figures by Country

3.4.1 North America GLP-1 Agonists for Obesity Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America GLP-1 Agonists for Obesity Sales by Country (2019-2030)

3.4.3 North America GLP-1 Agonists for Obesity Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe GLP-1 Agonists for Obesity Market Facts & Figures by Country

3.5.1 Europe GLP-1 Agonists for Obesity Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe GLP-1 Agonists for Obesity Sales by Country (2019-2030)

3.5.3 Europe GLP-1 Agonists for Obesity Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific GLP-1 Agonists for Obesity Market Facts & Figures by Region

3.6.1 Asia Pacific GLP-1 Agonists for Obesity Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific GLP-1 Agonists for Obesity Sales by Region (2019-2030)

3.6.3 Asia Pacific GLP-1 Agonists for Obesity Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America GLP-1 Agonists for Obesity Market Facts & Figures by Country

3.7.1 Latin America GLP-1 Agonists for Obesity Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America GLP-1 Agonists for Obesity Sales by Country (2019-2030)

3.7.3 Latin America GLP-1 Agonists for Obesity Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa GLP-1 Agonists for Obesity Market Facts & Figures by Country

3.8.1 Middle East and Africa GLP-1 Agonists for Obesity Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa GLP-1 Agonists for Obesity Sales by Country (2019-2030)

3.8.3 Middle East and Africa GLP-1 Agonists for Obesity Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global GLP-1 Agonists for Obesity Sales by Type (2019-2030)

4.1.1 Global GLP-1 Agonists for Obesity Sales by Type (2019-2024)

4.1.2 Global GLP-1 Agonists for Obesity Sales by Type (2025-2030)

4.1.3 Global GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2030)

4.2 Global GLP-1 Agonists for Obesity Revenue by Type (2019-2030)

4.2.1 Global GLP-1 Agonists for Obesity Revenue by Type (2019-2024)

4.2.2 Global GLP-1 Agonists for Obesity Revenue by Type (2025-2030)

4.2.3 Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2019-2030)

4.3 Global GLP-1 Agonists for Obesity Price by Type (2019-2030)

5 Segment by Application

5.1 Global GLP-1 Agonists for Obesity Sales by Application (2019-2030)

5.1.1 Global GLP-1 Agonists for Obesity Sales by Application (2019-2024)

5.1.2 Global GLP-1 Agonists for Obesity Sales by Application (2025-2030)

5.1.3 Global GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2030)

5.2 Global GLP-1 Agonists for Obesity Revenue by Application (2019-2030)

5.2.1 Global GLP-1 Agonists for Obesity Revenue by Application (2019-2024)

5.2.2 Global GLP-1 Agonists for Obesity Revenue by Application (2025-2030)

5.2.3 Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2019-2030)

5.3 Global GLP-1 Agonists for Obesity Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Company Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk GLP-1 Agonists for Obesity Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Novo Nordisk GLP-1 Agonists for Obesity Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 Eli Lilly

6.2.1 Eli Lilly Company Information

6.2.2 Eli Lilly Description and Business Overview

6.2.3 Eli Lilly GLP-1 Agonists for Obesity Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Eli Lilly GLP-1 Agonists for Obesity Product Portfolio

6.2.5 Eli Lilly Recent Developments/Updates

6.3 Huadong Medicine

6.3.1 Huadong Medicine Company Information

6.3.2 Huadong Medicine Description and Business Overview

6.3.3 Huadong Medicine GLP-1 Agonists for Obesity Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Huadong Medicine GLP-1 Agonists for Obesity Product Portfolio

6.3.5 Huadong Medicine Recent Developments/Updates

6.4 Shanghai Benemae Pharmaceutical Corporation

6.4.1 Shanghai Benemae Pharmaceutical Corporation Company Information

6.4.2 Shanghai Benemae Pharmaceutical Corporation Description and Business Overview

6.4.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product Portfolio

6.4.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 GLP-1 Agonists for Obesity Industry Chain Analysis

7.2 GLP-1 Agonists for Obesity Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 GLP-1 Agonists for Obesity Production Mode & Process

7.4 GLP-1 Agonists for Obesity Sales and Marketing

7.4.1 GLP-1 Agonists for Obesity Sales Channels

7.4.2 GLP-1 Agonists for Obesity Distributors

7.5 GLP-1 Agonists for Obesity Customers

8 GLP-1 Agonists for Obesity Market Dynamics

8.1 GLP-1 Agonists for Obesity Industry Trends

8.2 GLP-1 Agonists for Obesity Market Drivers

8.3 GLP-1 Agonists for Obesity Market Challenges

8.4 GLP-1 Agonists for Obesity Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Novo

Novo Nordisk

Eli Lilly

Huadong Medicine

Shanghai Benemae Pharmaceutical Corporation

List of Tables

Table 1. Global GLP-1 Agonists for Obesity Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global GLP-1 Agonists for Obesity Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global GLP-1 Agonists for Obesity Market Competitive Situation by Manufacturers in 2023

Table 4. Global GLP-1 Agonists for Obesity Sales (K Dose) of Key Manufacturers (2019-2024)

Table 5. Global GLP-1 Agonists for Obesity Sales Market Share by Manufacturers (2019-2024)

Table 6. Global GLP-1 Agonists for Obesity Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global GLP-1 Agonists for Obesity Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market GLP-1 Agonists for Obesity Average Price (US$/Dose) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of GLP-1 Agonists for Obesity, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of GLP-1 Agonists for Obesity, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of GLP-1 Agonists for Obesity, Product Type & Application

Table 12. Global Key Manufacturers of GLP-1 Agonists for Obesity, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global GLP-1 Agonists for Obesity by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Agonists for Obesity as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global GLP-1 Agonists for Obesity Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global GLP-1 Agonists for Obesity Sales by Region (2019-2024) & (K Dose)

Table 18. Global GLP-1 Agonists for Obesity Sales Market Share by Region (2019-2024)

Table 19. Global GLP-1 Agonists for Obesity Sales by Region (2025-2030) & (K Dose)

Table 20. Global GLP-1 Agonists for Obesity Sales Market Share by Region (2025-2030)

Table 21. Global GLP-1 Agonists for Obesity Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global GLP-1 Agonists for Obesity Revenue Market Share by Region (2019-2024)

Table 23. Global GLP-1 Agonists for Obesity Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global GLP-1 Agonists for Obesity Revenue Market Share by Region (2025-2030)

Table 25. North America GLP-1 Agonists for Obesity Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)

Table 27. North America GLP-1 Agonists for Obesity Sales by Country (2025-2030) & (K Dose)

Table 28. North America GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America GLP-1 Agonists for Obesity Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe GLP-1 Agonists for Obesity Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)

Table 32. Europe GLP-1 Agonists for Obesity Sales by Country (2025-2030) & (K Dose)

Table 33. Europe GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe GLP-1 Agonists for Obesity Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific GLP-1 Agonists for Obesity Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific GLP-1 Agonists for Obesity Sales by Region (2019-2024) & (K Dose)

Table 37. Asia Pacific GLP-1 Agonists for Obesity Sales by Region (2025-2030) & (K Dose)

Table 38. Asia Pacific GLP-1 Agonists for Obesity Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific GLP-1 Agonists for Obesity Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America GLP-1 Agonists for Obesity Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)

Table 42. Latin America GLP-1 Agonists for Obesity Sales by Country (2025-2030) & (K Dose)

Table 43. Latin America GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa GLP-1 Agonists for Obesity Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)

Table 47. Middle East and Africa GLP-1 Agonists for Obesity Sales by Country (2025-2030) & (K Dose)

Table 48. Middle East and Africa GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa GLP-1 Agonists for Obesity Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global GLP-1 Agonists for Obesity Sales (K Dose) by Type (2019-2024)

Table 51. Global GLP-1 Agonists for Obesity Sales (K Dose) by Type (2025-2030)

Table 52. Global GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)

Table 53. Global GLP-1 Agonists for Obesity Sales Market Share by Type (2025-2030)

Table 54. Global GLP-1 Agonists for Obesity Revenue (US$ Million) by Type (2019-2024)

Table 55. Global GLP-1 Agonists for Obesity Revenue (US$ Million) by Type (2025-2030)

Table 56. Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2019-2024)

Table 57. Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2025-2030)

Table 58. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Type (2019-2024)

Table 59. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Type (2025-2030)

Table 60. Global GLP-1 Agonists for Obesity Sales (K Dose) by Application (2019-2024)

Table 61. Global GLP-1 Agonists for Obesity Sales (K Dose) by Application (2025-2030)

Table 62. Global GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2024)

Table 63. Global GLP-1 Agonists for Obesity Sales Market Share by Application (2025-2030)

Table 64. Global GLP-1 Agonists for Obesity Revenue (US$ Million) by Application (2019-2024)

Table 65. Global GLP-1 Agonists for Obesity Revenue (US$ Million) by Application (2025-2030)

Table 66. Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2019-2024)

Table 67. Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2025-2030)

Table 68. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Application (2019-2024)

Table 69. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Application (2025-2030)

Table 70. Novo Nordisk Company Information

Table 71. Novo Nordisk Description and Business Overview

Table 72. Novo Nordisk GLP-1 Agonists for Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 73. Novo Nordisk GLP-1 Agonists for Obesity Product

Table 74. Novo Nordisk Recent Developments/Updates

Table 75. Eli Lilly Company Information

Table 76. Eli Lilly Description and Business Overview

Table 77. Eli Lilly GLP-1 Agonists for Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 78. Eli Lilly GLP-1 Agonists for Obesity Product

Table 79. Eli Lilly Recent Developments/Updates

Table 80. Huadong Medicine Company Information

Table 81. Huadong Medicine Description and Business Overview

Table 82. Huadong Medicine GLP-1 Agonists for Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 83. Huadong Medicine GLP-1 Agonists for Obesity Product

Table 84. Huadong Medicine Recent Developments/Updates

Table 85. Shanghai Benemae Pharmaceutical Corporation Company Information

Table 86. Shanghai Benemae Pharmaceutical Corporation Description and Business Overview

Table 87. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 88. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product

Table 89. Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates

Table 90. Key Raw Materials Lists

Table 91. Raw Materials Key Suppliers Lists

Table 92. GLP-1 Agonists for Obesity Distributors List

Table 93. GLP-1 Agonists for Obesity Customers List

Table 94. GLP-1 Agonists for Obesity Market Trends

Table 95. GLP-1 Agonists for Obesity Market Drivers

Table 96. GLP-1 Agonists for Obesity Market Challenges

Table 97. GLP-1 Agonists for Obesity Market Restraints

Table 98. Research Programs/Design for This Report

Table 99. Key Data Information from Secondary Sources

Table 100. Key Data Information from Primary Sources

Table 101. Authors List of This Report

List of Figures

Figure 1. Product Picture of GLP-1 Agonists for Obesity

Figure 2. Global GLP-1 Agonists for Obesity Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global GLP-1 Agonists for Obesity Market Share by Type: 2023 & 2030

Figure 4. Semaglutide Product Picture

Figure 5. Tirzepatide Product Picture

Figure 6. Liraglutide Product Picture

Figure 7. Benaglutide Product Picture

Figure 8. Global GLP-1 Agonists for Obesity Market Value by Application (2024-2030) & (US$ Million)

Figure 9. Global GLP-1 Agonists for Obesity Market Share by Application: 2023 & 2030

Figure 10. Hospital Pharmaty

Figure 11. Retail Pharmaty

Figure 12. Others

Figure 13. Global GLP-1 Agonists for Obesity Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global GLP-1 Agonists for Obesity Market Size (2019-2030) & (US$ Million)

Figure 15. Global GLP-1 Agonists for Obesity Sales (2019-2030) & (K Dose)

Figure 16. Global GLP-1 Agonists for Obesity Average Price (US$/Dose) & (2019-2030)

Figure 17. GLP-1 Agonists for Obesity Report Years Considered

Figure 18. GLP-1 Agonists for Obesity Sales Share by Manufacturers in 2023

Figure 19. Global GLP-1 Agonists for Obesity Revenue Share by Manufacturers in 2023

Figure 20. Global 5 and 10 Largest GLP-1 Agonists for Obesity Players: Market Share by Revenue in GLP-1 Agonists for Obesity in 2023

Figure 21. GLP-1 Agonists for Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 22. Global GLP-1 Agonists for Obesity Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2030)

Figure 24. North America GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2030)

Figure 25. United States GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2030)

Figure 28. Europe GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2030)

Figure 29. Germany GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific GLP-1 Agonists for Obesity Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific GLP-1 Agonists for Obesity Revenue Market Share by Region (2019-2030)

Figure 36. China GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. China Taiwan GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Southeast Asia GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Latin America GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2030)

Figure 44. Mexico GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Brazil GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Argentina GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Colombia GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Middle East and Africa GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2030)

Figure 49. Middle East and Africa GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2030)

Figure 50. Turkey GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Saudi Arabia GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. UAE GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Global Sales Market Share of GLP-1 Agonists for Obesity by Type (2019-2030)

Figure 54. Global Revenue Market Share of GLP-1 Agonists for Obesity by Type (2019-2030)

Figure 55. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Type (2019-2030)

Figure 56. Global Sales Market Share of GLP-1 Agonists for Obesity by Application (2019-2030)

Figure 57. Global Revenue Market Share of GLP-1 Agonists for Obesity by Application (2019-2030)

Figure 58. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Application (2019-2030)

Figure 59. GLP-1 Agonists for Obesity Value Chain

Figure 60. GLP-1 Agonists for Obesity Production Process

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Oral GLP 1 Agonist Market Research Report 2024

Global Glucagon Like Peptide 1 GLP 1 Agonists Market Research Report 2025

Global Antidiabetic Glucagon like Peptide 1 Agonists Market Research Report 2025

Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2025

Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024

GLP Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1 Receptor Agonist Drugs Market Research Report 2024

GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1 Weight Loss Drug Market Research Report 2024

Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024

Global GLP 1 Receptor Antagonist Market Research Report 2024

GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1 Drug Peptide API Market Research Report 2024

Global GLP 1 Weight Loss Pill Market Research Report 2024

Global GLP 1 Weight Loss Injection Market Research Report 2024

Global GLP 1 Drugs Market Research Report 2024

Global GLP 1 based Therapy Market Research Report 2024

Global GLP 1RA based Therapy for Obesity Market Research Report 2024

Global GLP 1RA Therapy Market Research Report 2024

RELATED REPORTS

Global Bariatric Surgical Procedures Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-36T5954

Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Obesity Management Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-37J2827

Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Obesity Surgery Devices Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-0M7800

Tue Sep 02 00:00:00 UTC 2025

Add to Cart

Global Gastric Band Devices Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-6J7573

Wed Aug 27 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions